Aquestive Therapeutics In... (AQST)
Aquestive Therapeutics Statistics
Share Statistics
Aquestive Therapeutics has 98.87M shares outstanding. The number of shares has increased by 1.35% in one year.
| Shares Outstanding | 98.87M |
| Shares Change (YoY) | 1.35% |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | 47.62% |
| Shares Floating | 87.78M |
| Failed to Deliver (FTD) Shares | 38 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 11.79M, so 12.93% of the outstanding shares have been sold short.
| Short Interest | 11.79M |
| Short % of Shares Out | 12.93% |
| Short % of Float | 15.19% |
| Short Ratio (days to cover) | 7.25 |
Valuation Ratios
The PE ratio is -7 and the forward PE ratio is -5.84. Aquestive Therapeutics's PEG ratio is -0.02.
| PE Ratio | -7 |
| Forward PE | -5.84 |
| PS Ratio | 5.36 |
| Forward PS | 1.2 |
| PB Ratio | -5.13 |
| P/FCF Ratio | -8.6 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Aquestive Therapeutics Inc. has an Enterprise Value (EV) of 198.69M.
| EV / Earnings | -4.5 |
| EV / Sales | 3.45 |
| EV / EBITDA | -7.46 |
| EV / EBIT | -6.46 |
| EV / FCF | -5.53 |
Financial Position
The company has a current ratio of 4.68, with a Debt / Equity ratio of -0.63.
| Current Ratio | 4.68 |
| Quick Ratio | 4.36 |
| Debt / Equity | -0.63 |
| Total Debt / Capitalization | -171.56 |
| Cash Flow / Debt | -0.94 |
| Interest Coverage | -1.83 |
Financial Efficiency
Return on equity (ROE) is 0.73% and return on capital (ROIC) is 138.86%.
| Return on Equity (ROE) | 0.73% |
| Return on Assets (ROA) | -0.44% |
| Return on Capital (ROIC) | 138.86% |
| Revenue Per Employee | $405,359.15 |
| Profits Per Employee | $-310,823.94 |
| Employee Count | 142 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.96 |
Taxes
| Income Tax | -14K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -24.15% in the last 52 weeks. The beta is 2.76, so Aquestive Therapeutics's price volatility has been higher than the market average.
| Beta | 2.76 |
| 52-Week Price Change | -24.15% |
| 50-Day Moving Average | 2.99 |
| 200-Day Moving Average | 3.78 |
| Relative Strength Index (RSI) | 55.16 |
| Average Volume (20 Days) | 1.69M |
Income Statement
In the last 12 months, Aquestive Therapeutics had revenue of 57.56M and earned -44.14M in profits. Earnings per share was -0.51.
| Revenue | 57.56M |
| Gross Profit | 39.69M |
| Operating Income | -30.77M |
| Net Income | -44.14M |
| EBITDA | -26.62M |
| EBIT | -30.77M |
| Earnings Per Share (EPS) | -0.51 |
Balance Sheet
The company has 71.55M in cash and 38M in debt, giving a net cash position of 33.54M.
| Cash & Cash Equivalents | 71.55M |
| Total Debt | 38M |
| Net Cash | 33.54M |
| Retained Earnings | -363.21M |
| Total Assets | 101.42M |
| Working Capital | 69.36M |
Cash Flow
In the last 12 months, operating cash flow was -35.76M and capital expenditures -159K, giving a free cash flow of -35.92M.
| Operating Cash Flow | -35.76M |
| Capital Expenditures | -159K |
| Free Cash Flow | -35.92M |
| FCF Per Share | -0.41 |
Margins
Gross margin is 68.95%, with operating and profit margins of -53.46% and -76.68%.
| Gross Margin | 68.95% |
| Operating Margin | -53.46% |
| Pretax Margin | -76.7% |
| Profit Margin | -76.68% |
| EBITDA Margin | -46.24% |
| EBIT Margin | -53.46% |
| FCF Margin | -62.4% |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -16.4% |
| FCF Yield | -11.68% |
Analyst Forecast
The average price target for AQST is $9.5, which is 205.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.5 |
| Price Target Difference | 205.5% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -3.38 |
| Piotroski F-Score | 3 |